3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope–specific plasma cells and humoral immunity in nonhuman primates
Open Access
- 26 June 2020
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 5 (48)
- https://doi.org/10.1126/sciimmunol.abb1025
Abstract
A fundamental challenge in vaccinology is learning how to induce durable antibody responses. Live viral vaccines induce antibody responses that last a lifetime, but those induced with subunit vaccines wane rapidly. Studies in mice and humans have established that long-lived plasma cells (LLPCs) in the bone marrow (BM) are critical mediators of durable antibody responses. Here, we present data that adjuvanting an HIV-1 clade C 1086.C–derived gp140 immunogen (Env) with a novel synthetic Toll-like receptor (TLR)–7/8 agonist named 3M-052 formulated in poly(lactic-co-glycolic)acid or PLGA nanoparticles (NPs) or with alum, either alone or in combination with a TLR-4 agonist GLA, induces notably high and persistent (up to ~1 year) frequencies of Env-specific LLPCs in the BM and serum antibody responses in rhesus macaques. Up to 36 and 18% of Env-specific cells among total IgG-secreting BM-resident plasma cells were detected at peak and termination, respectively. In contrast, adjuvanting Env with alum or GLA in NP induced significantly lower (~FH) cells, and persistent Env-specific plasma cells in draining lymph nodes. Overall, these results demonstrate efficacy of 3M-052 in promoting high magnitude and durability of antibody responses via robust stimulation of innate immunity and BM-resident LLPCs.Keywords
Funding Information
- Bill and Melinda Gates Foundation (INV-002147)
This publication has 74 references indexed in Scilit:
- Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy TrialThe New England Journal of Medicine, 2012
- High‐throughput quantitative analysis of HIV‐1 and SIV‐specific ADCC‐mediating antibody responsesCytometry Part A, 2011
- Prevention of Infection by a Granulocyte-Macrophage Colony-Stimulating Factor Co-Expressing DNA/Modified Vaccinia Ankara Simian Immunodeficiency Virus VaccineThe Journal of Infectious Diseases, 2011
- Programming the magnitude and persistence of antibody responses with innate immunityNature, 2011
- Vaccine Adjuvants: Putting Innate Immunity to WorkImmunity, 2010
- Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in ThailandThe New England Journal of Medicine, 2009
- Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigenNature Protocols, 2009
- Rapid cloning of high-affinity human monoclonal antibodies against influenza virusNature, 2008
- GM-CSF DNA: An adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccineVirology, 2007
- Adjuvant-Enhanced Antibody Responses in the Absence of Toll-Like Receptor SignalingScience, 2006